Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation

被引:65
作者
Calvo, F. A.
Serrano, F. J.
Diaz-Gonzalez, J. A.
Gomez-Espi, M.
Lozano, E.
Garcia, R.
de la Mata, D.
Arranz, J. A.
Garcia-Alfonso, P.
Perez-Manga, G.
Alvarez, E.
机构
[1] Hosp Gen Univ Gregorio Maranon, Dept Oncol, Madrid 28007, Spain
[2] Hosp Gen Univ Gregorio Maranon, Radiat Oncol Serv, Madrid 28007, Spain
[3] Hosp Gen Univ Gregorio Maranon, Dept Pathol, Madrid 28007, Spain
关键词
neoadjuvant oxaliplatin; chemoradiation; tegafur; rectal cancer; downstaging;
D O I
10.1093/annonc/mdl085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare efficacy in terms of pathologic response in LARC patients treated with preoperative chemoradiation, with or without a short-intense course of induction oxaliplatin. Patients and Methods: From 05/98 to 10/02, 114 patients were treated with preoperative chemoradiation (4500-5040 cGy + oral Tegafur 1200 mg/day) for cT(3)-4N+/xM0 rectal cancer. Starting 05/01, 52 consecutive patients additionally received induction FOLFOX-4, oxaliplatin (85 mg/m(2) iv d1), 5-FU (400 mg/m(2) iv bolus d1) and 600 mg/m(2) iv continuous infusion in 22 h with leucovorin (200 mg iv) d1 and d2, every 15 days (2 cycles), followed by the previously described Tegafur chemoradiation regime. Surgery was performed in 5-6 weeks. Pathological assessment investigated post-treatment T and N status in the rectal wall and peri-rectal tissues. Results: Patients, tumor and treatment characteristics were comparable between groups. Incidence of pT(0) specimens was significantly increased by induction FOLFOX-4 (P = 0.006). Total T and N downstaging were 58% versus 75% and 42% versus 40%, respectively (P = ns). T downstaging of >= 2 categories was significantly superior in FOLFOX-4 group (P = 0.029). Conclusions: Short-intense induction FOLFOX-4 significantly improves pathologic complete response in LARC patients treated with tegafur-sensitized preoperative chemoradiation. The 44% rate of pT(0)-(1) specimens observed in the oxaliplatin group should impulse innovative surgical approaches to promote ano-rectal sphincter conserving protocols.
引用
收藏
页码:1103 / 1110
页数:8
相关论文
共 58 条
[1]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]  
[Anonymous], 1995, INT J RAD ONCOLOGY B, V31, P1049, DOI DOI 10.1016/0360-3016(95)90159-0
[3]   A phase I-II study of weekly oxaliplatin, 5-fiuorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer [J].
Aschele, C ;
Friso, ML ;
Pucciarelli, S ;
Lonardi, S ;
Sartor, L ;
Fabris, G ;
Urso, EDL ;
Del Bianco, P ;
Sotti, G ;
Lise, M ;
Monfardini, S .
ANNALS OF ONCOLOGY, 2005, 16 (07) :1140-1146
[4]   Preoperative radiotherapy (RT) for rectal cancer: Predictive factors of tumor downstaging and residual tumor cell density (RTCD): Prognostic implications [J].
Berger, C ;
deMuret, A ;
Garaud, P ;
Chapet, S ;
Bourlier, P ;
ReynaudBougnoux, A ;
Dorval, E ;
deCalan, L ;
Huten, N ;
leFloch, O ;
Calais, G .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (03) :619-627
[5]   Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients [J].
Bonnen, M ;
Crane, C ;
Vauthey, JN ;
Skibber, J ;
Delclos, ME ;
Rodriguez-Bigas, M ;
Hoff, PM ;
Lin, E ;
Eng, C ;
Wong, A ;
Janjan, NA ;
Feig, BW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (04) :1098-1105
[6]   Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: Preliminary results - EORTC 22921 [J].
Bosset, JF ;
Calais, G ;
Mineur, L ;
Maingon, P ;
Radosevic-Jelic, L ;
Daban, A ;
Bardet, E ;
Beny, A ;
Briffaux, A ;
Collette, L .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5620-5627
[7]   Preoperative radiochemotherapy in rectal cancer: Long-term results of a phase II trial [J].
Bosset, JF ;
Magnin, V ;
Maingon, P ;
Mantion, G ;
Pelissier, EP ;
Mercier, M ;
Chaillard, G ;
Horiot, JC .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (02) :323-327
[8]   Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy [J].
Bujko, K ;
Nowacki, MP ;
Nasierowska-Guttmejer, A ;
Michalski, W ;
Bebenek, AB ;
Pudelko, M ;
Kryj, A ;
Oledzki, J ;
Szmeja, J ;
Sluszniak, J ;
Serkies, K ;
Kladny, J ;
Pamucka, A ;
Kukolowicz, P .
RADIOTHERAPY AND ONCOLOGY, 2004, 72 (01) :15-24
[9]   18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation [J].
Calvo, FA ;
Domper, M ;
Matute, R ;
Martínez-Lázaro, R ;
Arranz, JA ;
Desco, M ;
Alvarez, E ;
Carreras, JL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (02) :528-535
[10]   Intraoperative presacral electron boost following preoperative chemoradiation in T3-4NX rectal cancer:: initial local effects and clinical outcome analysis [J].
Calvo, FA ;
Gómez-Espí, M ;
Díaz-González, JA ;
Alvarado, A ;
Cantalapiedra, R ;
Marcos, P ;
Matute, R ;
Martínez, NE ;
Lozano, MA ;
Herranz, R .
RADIOTHERAPY AND ONCOLOGY, 2002, 62 (02) :201-206